Further pharmacological medicaments for the treatment of NASH are hydrophilic bile acids (BAs), which can modulate both glucose and lipid handling [148] through the activation of farnesoid X receptor (FXR) [149,150] and Takeda G protein-coupled receptor 5 (TGR5) [151], displaying a significant anti-inflammatory activity [152]. This evidence concerns the gene GPBAR1 and metabolic dysfunction-associated steatohepatitis.